0% 13.7% Sham Zenkuda 0% 5.6% 0% 5% 10% 15% 20% 25% Sham Zenkuda Zenkuda in Diabetic Retinopathy: Zenkuda established superiority in ≥3-step improvement in DR Severity Score (DRSS) in GLOW1 and GLOW2 GLOW1 GLOW2 Proportion of patients with ≥3-Step improvement in DRSS from Baseline to Week 48 GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130); Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates p=0.0058 p<0.0001 Phase 3 GLOW1 GLOW2 Superiority 6-month Durability 100% of patients on 6-month dosing at Year 1 30